ObjectivesMultiple primary lung cancers (MPLCs) are an increasingly well-known clinical phenomenon, but there is a lack of high-level evidence for their optimal clinical diagnosis and therapeutic approaches. Thus, we analysed genetic variation to determine the intertumoural heterogeneity and branch evolution of synchronous multiple primary lung adenocarcinomas.MethodsWe performed multiplex mutational sequencing on 93 synchronous multiple primary lung adenocarcinoma lesions from 42 patients who underwent surgical resection.ResultsThe high discordance rate of mutation was 92.9% (n=39) between tumours in individual patients. EGFR, TP53 and KRAS mutations were detected in 57 (61.3%), 19 (20.4%) and 11 (11.8%) of the 93 tumours, respectively. 16...
Synchronous double primary lung squamous carcinoma (sDPLSCC) is rare and difficult to distinguish fr...
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. Howeve...
Objective: For treatment decisions and prognostic applications, we evaluated p53/epidermal growth fa...
Background and objective With the popularization of high-resolution computed tomography (HRCT), ther...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
Discovery of driver mutations in pulmonary adenocarcinoma has revolutionized the field of thoracic o...
Discrimination of multifocal primary lung cancers from lung metastases is crucial to allow for an ap...
Abstract Background Multiple primary malignant tumors (MPMT) refers to the presence of two or more p...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
In recent years, based on low-dose computed tomography (CT) scan developed for physical examination,...
Synchronous multiple small adenocarcinomas are detected more frequently than in the past; however, t...
Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclon...
Yi Bao,1,2 Jiayuan Wu,1 Jun Zhang,3 Yawei Yu41The Key Laboratory, The Second Affiliated Hospital of ...
Differentiation between multiple primary lung cancers and pulmonary metastases (PM) has important im...
In recent years, the spread of more-sensitive diagnostic methods has resulted in an increase of sync...
Synchronous double primary lung squamous carcinoma (sDPLSCC) is rare and difficult to distinguish fr...
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. Howeve...
Objective: For treatment decisions and prognostic applications, we evaluated p53/epidermal growth fa...
Background and objective With the popularization of high-resolution computed tomography (HRCT), ther...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
Discovery of driver mutations in pulmonary adenocarcinoma has revolutionized the field of thoracic o...
Discrimination of multifocal primary lung cancers from lung metastases is crucial to allow for an ap...
Abstract Background Multiple primary malignant tumors (MPMT) refers to the presence of two or more p...
With the development of technologies, multiple primary lung cancer (MPLC) has been detected more fre...
In recent years, based on low-dose computed tomography (CT) scan developed for physical examination,...
Synchronous multiple small adenocarcinomas are detected more frequently than in the past; however, t...
Several studies have shown heterogeneity in lung cancer, with parallel existence of multiple subclon...
Yi Bao,1,2 Jiayuan Wu,1 Jun Zhang,3 Yawei Yu41The Key Laboratory, The Second Affiliated Hospital of ...
Differentiation between multiple primary lung cancers and pulmonary metastases (PM) has important im...
In recent years, the spread of more-sensitive diagnostic methods has resulted in an increase of sync...
Synchronous double primary lung squamous carcinoma (sDPLSCC) is rare and difficult to distinguish fr...
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. Howeve...
Objective: For treatment decisions and prognostic applications, we evaluated p53/epidermal growth fa...